BioSpace News Archive

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for the treatment of chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough, announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that two poster presentations highlighting ongoing global clinical studies in its oncology pipeline will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024, in San Diego, California.

Arthrex, a global leader in minimally invasive surgical technology, announced the 10th anniversary of the InternalBrace™ ligament augmentation system.

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the first quarter 2024 after the close of trading on Tuesday, May 7.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT.

Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 23rd Annual Needham Virtual Healthcare Conference at 8:00 AM ET on Monday, April 8, 2024.

MaxCyte, Inc. and Be Biopharma announced the signing of a strategic platform license to support the development of Be Bio’s BCMs programs.

Anika Therapeutics, Inc. today announced that management will participate in the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024.

Apollomics Inc. today announced poster presentations on vebreltinib (APL-101) at the 2024 American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, Calif.